Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) reported new Phase 1b/2a RESOLVE trial data for EP-104GI in eosinophilic esophagitis, including the first detailed analysis of odynophagia (painful swallowing) symptom scores.
Among Cohorts 7-9 (20 injections; 80–160 mg total dose), the proportion of patients with moderate or severe odynophagia fell from 62% at baseline to 31% at weeks 2–12 and 25% at weeks 24, 36 and 52; severe odynophagia, reported by 23% at baseline, was absent at weeks 24 and 52. Patients with no odynophagia increased from 15% at baseline to 50% at week 52.
For dysphagia (difficulty swallowing), moderate or severe cases declined from 77% at baseline to 54% at week 12 and 25% at weeks 24 and 52; severe dysphagia (31% at baseline) was not seen at weeks 24 and 52. According to Eupraxia, over 130 patients have received EP-104GI or placebo across RESOLVE (over 2,000 injection sites) with no treatment-emergent or procedure-related serious adverse events and no concerns regarding mean glucose or cortisol levels. The randomized, placebo-controlled Phase 2b portion is recruiting 120 mg and 160 mg doses, with an interim readout expected in Q4 2026.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) reported a Q2 2026 net loss of $14.5 million, compared with $8.7 million a year earlier, mainly from higher research and development and general and administrative expenses linked to expanding its RESOLVE Part 2 trial in eosinophilic esophagitis (EoE).
The company held $52.4 million in cash and cash equivalents and $81.2 million in short-term investments at June 30, 2026, up from an aggregate $80.6 million at the end of Q4 2025, and expects its cash to fund operations into the second half of 2028.
New RESOLVE trial data presented at DDW showed improved inflammation and fibrosis and 66% symptom remission at week 36 in the highest-dose cohort (2 of 3 patients). Eupraxia also strengthened its executive team and board, and shifted to a Vancouver–Seattle operational hub structure.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced key executive and organizational changes to support its transition toward later-stage clinical and commercial development. Effective July 13, 2026, Dr. Jeff Millard joins as Executive Vice President, Technical Operations, bringing about 25 years of experience in technical operations, CMC and regulatory strategy, and will lead these functions for Eupraxia with a focus on EP104GI.
Dr. Alex Therien, who joined in November 2025, becomes Executive Vice President, Research & Development, taking leadership of R&D to drive portfolio expansion. The company has shifted its operational hubs from Victoria to Vancouver and Seattle, with key clinical, manufacturing and commercial leadership, including the CEO, based in Seattle. As part of this transition, Chief Scientific and Operating Officer Amanda Malone, based in Victoria, stepped down effective July 10, 2026. Eupraxia highlights its Phase 1b/2 RESOLVE trial of EP-104GI in EoE, a completed Phase 2b SPRINGBOARD trial of EP-104IAR in knee osteoarthritis that met its primary endpoint, and its broader pipeline using its Diffusphere™ drug delivery platform.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) appointed Robert Bazemore, Amy Pott and Dr. Helen Thackray to its Board of Directors.
Their backgrounds span 30+ years in novel medicine development, late-stage clinical programs, global product launches and commercialization, supporting upcoming milestones for EP-104GI and expansion of Eupraxia’s gastroenterology-focused pipeline and Diffusphere™ platform.
Eupraxia Pharmaceuticals (TSX/NASDAQ:EPRX) reported voting results from its June 18, 2026 Annual General Meeting. All seven management-nominated directors were elected, each receiving over 91% of votes cast, and KPMG LLP was re-appointed as auditor for the coming year.
The company highlighted its Diffusphere™ drug-delivery platform, its Phase 1b/2 RESOLVE trial of EP-104GI for EoE, and the completed Phase 2b SPRINGBOARD trial of EP-104IAR for knee osteoarthritis, which met its primary endpoint and three of four secondary endpoints.
Eupraxia Pharmaceuticals (NASDAQ:EPRX), a clinical-stage biotechnology company using its Diffusphere™ drug delivery technology, will present at the Jefferies Global Healthcare Conference in New York.
The management presentation is scheduled for June 3, 2026, from 5:30–6:00 PM ET, with 1x1 meetings on June 3–4 and a webcast available.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) reported Q1 2026 results and clinical progress for EP-104GI in Eosinophilic Esophagitis.
Net loss was $12.7 million versus $6.8 million a year earlier. Cash and equivalents were $58.5 million plus $80.4 million in short-term investments, supported by a completed $63.2 million public offering.
The company reports robust, durable responses in the highest-dose cohort of the RESOLVE trial and expects existing cash and warrant proceeds to fund operations into H2 2028. As of March 31, 2026, there were 61.8 million common and 8.4 million preferred shares outstanding.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) released first EoEHSS sub score data from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis, presented at Digestive Disease Week on May 6, 2026. Improvements in inflammation (EoEHSS-i) and architecture/fibrosis (EoEHSS-a) were reported at 12 weeks (n=31) and 36 weeks (n=27).
The largest responses occurred in the highest-dose cohort (cohort 9): EoEHSS-i grade and stage improved by >90% at weeks 12 and 36; EoEHSS-a grade and stage improved by >83% at weeks 12 and 36. Some cohort 36-week data remain pending (cohort 8b).
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported EREFS endoscopic data from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis on May 5, 2026. The data show an association between the number of injections and EREFS improvement, with a 20-injection protocol producing the largest mean EREFS reduction.
Among 7 patients with baseline EREFS >2 who received 20 injections, mean EREFS fell by 65% (3.6 points) at week 12; highest-dose cohorts (8b and 9, combined n=4) showed near-complete EREFS improvement.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced on May 1, 2026 the appointment of Dr. Jeymi Tambiah as Chief Medical Officer and the retirement of Dr. Mark Kowalski, who will support the company as a senior consultant during transition.
Dr. Tambiah brings over 18 years of clinical development, regulatory and commercialization experience and will support late‑stage development of EP‑104GI in eosinophilic esophagitis and expansion of the gastroenterology pipeline using the Diffusphere™ platform.